Role of transcription factor modifications in the pathogenesis of insulin resistance by 源�誘몄쁺 et al.
Hindawi Publishing Corporation
Experimental Diabetes Research
Volume 2012, Article ID 716425, 16 pages
doi:10.1155/2012/716425
Review Article
Role of Transcription Factor Modifications in the
Pathogenesis of Insulin Resistance
Mi-Young Kim,1, 2 Jin-Sik Bae,1, 2 Tae-Hyun Kim,1, 2 Joo-Man Park,1, 2, 3 and Yong Ho Ahn1, 2, 3
1Department of Biochemistry and Molecular Biology, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu,
Seoul 120-752, Republic of Korea
2Center for Chronic Metabolic Disease Research, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu,
Seoul 120-752, Republic of Korea
3Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu,
Seoul 120-752, Republic of Korea
Correspondence should be addressed to Yong Ho Ahn, yha111@yuhs.ac
Received 26 May 2011; Accepted 25 July 2011
Academic Editor: Faidon Magkos
Copyright © 2012 Mi-Young Kim et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Non-alcoholic fatty liver disease (NAFLD) is characterized by fat accumulation in the liver not due to alcohol abuse. NAFLD is
accompanied by variety of symptoms related to metabolic syndrome. Although the metabolic link between NAFLD and insulin
resistance is not fully understood, it is clear that NAFLD is one of the main cause of insulin resistance. NAFLD is shown to aﬀect
the functions of other organs, including pancreas, adipose tissue, muscle and inflammatory systems. Currently eﬀorts are being
made to understand molecular mechanism of interrelationship between NAFLD and insulin resistance at the transcriptional level
with specific focus on post-translational modification (PTM) of transcription factors. PTM of transcription factors plays a key role
in controlling numerous biological events, including cellular energy metabolism, cell-cycle progression, and organ development.
Cell type- and tissue-specific reversible modifications include lysine acetylation, methylation, ubiquitination, and SUMOylation.
Moreover, phosphorylation and O-GlcNAcylation on serine and threonine residues have been shown to aﬀect protein stability,
subcellular distribution, DNA-binding aﬃnity, and transcriptional activity. PTMs of transcription factors involved in insulin-
sensitive tissues confer specific adaptive mechanisms in response to internal or external stimuli. Our understanding of the interplay
between these modifications and their eﬀects on transcriptional regulation is growing. Here, we summarize the diverse roles of
PTMs in insulin-sensitive tissues and their involvement in the pathogenesis of insulin resistance.
1. Posttranslational Modifications of
Transcription Factors: Relevance in
the Context of Metabolic Syndrome
Transcription is the seminal event in the expression of genes
and is a central point at which gene expression is regulated.
Many cellular processes, including those that are tissue-spe-
cific or developmentally related, are largely controlled at the
transcriptional level [1]. Transcription factors often regulate
the expression of genes by binding to specific consensus se-
quences, or cis elements, within promoter regions [2]. Once
bound, coregulators that either activate or repress tran-
scription are recruited [3, 4]. Transcription factors play
critical roles in regulating constitutive and inducible gene
expression. In response to cellular stimuli, these proteins can
be targets of modifications that aﬀect their stability, activity,
intracellular distribution, and interaction with other proteins
[5]. Diﬀerent external and internal signals direct distinct
patterns of posttranslational modifications (PTMs), which
transduce the signals for specific metabolic processes.
The number of people diagnosed with type 2 diabetes
mellitus (T2DM) worldwide has been estimated to exceed
200 million [6]. Left untreated or uncontrolled, this disease
can cause serious complications such as blindness, kidney
damage, and vascular damage that may require the ampu-
tation of limbs or digits. T2DM is characterized by defects
in both insulin sensitivity and secretion [7]. Central to this
defect is insulin resistance, which reflects impaired sensitivity
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of target organs—primarily liver, pancreas, adipose tissue,
and muscle—to insulin [8, 9]. Although the pathogenesis
of insulin resistance remains unclear, abnormal insulin sig-
naling [10], mitochondrial dysfunction [11], endoplasmic
reticulum (ER) stress [12], dysfunctional triglyceride/free
fatty acid cycle intermediates [13], and inflammation [14]
have been reported to be involved in mediating this disease.
These abnormalities lead to alterations in the transcription of
key metabolic genes accompanied by PTMs of transcription
factors that may result in the suppression or activation of
target genes.
Recent advances in the understanding of PTMs, includ-
ing those of transcription factors, have provided greater
insight into the altered gene regulation that results in insulin
resistance. Interestingly, multiple PTMs—both independent
and interdependent—can occur, creating the potential for
diverse cellular responses through changes at the transcrip-
tional level. In this paper, we will limit our discussion to
transcription factor PTMs responsible for metabolic alter-
ations associated with insulin resistance.
2. Types of Transcription Factor Modifications
PTMs could be considered an evolutionary solution to the
limited number of transcription factors, expanding the func-
tional repertoire of genetic regulatory elements to cover the
diverse metabolic requirements that are met through reg-
ulated gene expression. Although a large number of tran-
scription factors have been demonstrated to be modified by
PTM, there are still more left to be discovered. Furthermore,
the interrelationship between various types of PTM should
be understood in terms of modulating the DNA binding
activity, stability, localization, and protein-protein interac-
tions. Transcription factors can undergo several diﬀerent
types of PTMs, including acetylation, phosphorylation, gly-
cosylation, and ubiquitination. The transcription factors and
target genes considered in this paper are listed in Table 1. In
addition, the functions of PTM of transcription factors are
summarized in Figure 1.
2.1. Acetylation/Deacetylation. Acetylation of histone or
nonhistone proteins is critical for gene expression. This
modification, which occurs on lysine residues, aﬀects protein
stability, localization, degradation, and function. Moreover,
this modification can also influence protein-protein and
protein-DNA interactions. Interestingly, most acetylated
forms of nonhistone proteins have been shown to be involved
in tumorigenesis and immune function. Our understanding
of the role of acetylation of transcription factors involved in
insulin resistance is incomplete, but emerging evidence indi-
cates that acetylation influences the subcellular distribution,
DNA binding ability, and proteasomal degradation of these
proteins [15].
2.2. Phosphorylation/Dephosphorylation. External stimuli of-
ten lead to the activation of signal transduction pathways
that result in the phosphorylation of transcription factors.
Depending on the stimulus, specific amino acid residues,
typically tyrosine, serine, and/or threonine, are phosphory-
lated by one or more protein kinases. Dephosphorylation by
phosphatases can also occur in response to cellular signals.
This phosphorylation/dephosphorylation dynamic can di-
rectly regulate distinct aspects of transcription factor func-
tion, including subcellular distribution, DNA binding, trans-
acting ability, and protein stability [16, 17].
2.3. Modification by O-Linked-N-Acetylglucosamine: O-
GlcNAcylation. O-GlcNAcylation is a dynamic, inducible,
and reversible, nutrient-sensitive post-translational event in
which O-linked-N-acetylglucosamine (O-GlcNAc) is at-
tached to serine and/or threonine hydroxyl groups of cy-
tosolic [18], mitochondrial [19], or nuclear proteins [18] by
the concerted actions of O-GlcNAc transferase (OGT) and
O-GlcNAcase [18, 20].
UDP-GlcNAc is a major end product of the hexosamine
biosynthesis pathway and functions as a cellular nutrient
sensor. Sustained exposure to high concentrations of glucose
and glucosamine increases UDP-GlcNAc levels, which, in
turn, results in an increase in O-GlcNAc-glycosylated pro-
teins and leads to glucotoxicity in various insulin-sensitive
tissues [21]. Indeed, insulin-signaling molecules, including
the β subunit of the insulin receptor, insulin receptor
substrate (IRS)-1 and -2, the p85 and p110 subunits of
phosphoinositide 3-phosphate kinase (PI3K), protein kinase
B (PKB)/Akt, and 3-phosphoinositide-dependent protein
kinase-1 (PDK1), are targets of OGT, and O-GlcNAcylation
of these proteins causes downregulation of insulin signaling
[22].
2.4. Ubiquitination and SUMOylation. The amount of intra-
cellular protein is regulated by the rates of protein synthesis
and degradation. In general, protein degradation occurs via
the ubiquitin-proteasome pathway [23]. Ubiquitin, a highly
conserved protein consisting of 76 amino acids, is targeted to
substrate proteins and polymerized by the sequential action
of three enzymes: E1, a ubiquitin-activating enzyme; E2, a
ubiquitin-conjugating enzyme; E3, a ubiquitin-protein ligase
[24]. The resulting protein contains multiple chains of
branched ubiquitin molecules that enable recognition by the
26S proteasome, which subsequently mediates degradation
of the ubiquitinated protein into small peptides [24, 25].
In addition to ubiquitination, transcription factors can
also be modified by the addition of SUMO (small ubiquitin-
related modifier), a protein composed of 97 amino acids. In
this event, SUMO is attached to lysine residues in the sub-
strate protein by the sequential action of three enzymes [26].
SUMOylation can aﬀect protein stability, subcellular local-
ization, or protein-protein interactions [27, 28]. SUMOy-
lation often competes with ubiquitination and/or acet-
ylation for lysine residues on target transcription factors
[29, 30].
Reports have suggested that deregulated ubiquitin/
proteasome-mediated degradation of insulin signaling mole-
cules results in insulin resistance and the development of di-
abetes [31].
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Table 1: The target genes of the transcription factors.
Transcription factor
Target gene
Reference
Gene symbol Description
FOXO1 G6PC Glucose-6-phosphatase [36]
Pck1 Phosphoenolpyruvates carboxykinase1 [181]
Ppargc1a Peroxisome proliferator-activated receptor-coactivator-1 alpha [38]
Pdx1 Pancreatic and duodenal homeobox 1 [101]
NeuroD Neurogenic diﬀerentiation [107]
MafA V-maf (mafmusculoaponeurotic fibrosarcoma) oncogene homolog A [107]
ADIPOQ Adiponectin [170]
CREB G6pc Glucose-6-phosphatease [57]
Pck1 Phosphoenolpyruvates carboxykinase [57]
Ppargc1a Peroxisome proliferator-activated receptor-coactivator-1 alpha [57]
SREBP-1c ACLY ATP-citrate lyase
[182,
183]
Acaca Acetyl-CoA carboxylase alpha [184]
ACACB Acetyl-CoA carboxylase beta [185]
Fasn Fatty acid synthase [186]
Scd1 Stearoyl-coenzyme A desaturase 1 [187]
Elovl6 ELOVL fatty acid elongase 6 [188]
ChREBP Pklr Pyruvate kinase, liver, and RBC [189]
Acc1 Acetyl-CoA carboxylase 1 [190]
Fasn Fatty acid synthase [191]
NF-κB TNF-α Tumor necrosis factor alpha [192]
IL-6 Interleukin 6 [193]
MCP-1 Monocyte chemotactic protein 1 [194]
Sp1 LEP Leptin [195]
LETN Resistin [196]
P
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OGA
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HAT
SIRT
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Nuclear localization
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Transcription
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factors
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Figure 1: The types and functions of post-translational modification of transcription factors.
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3. Modification of Transcription Factors in
the Insulin-Sensitive Tissues
3.1. Liver Metabolism
3.1.1. Eﬀect of Transcription Factor Modifications on Hepatic
Gluconeogenesis. Hepatic gluconeogenesis is an essential
process during fasting or starvation. However, activation of
gluconeogenesis in patients with T2DM causes hyper-
glycemia. Insulin has been shown to suppress gluconeoge-
nesis in the liver [32]. When insulin binds to its receptor,
signal transduction pathways are activated that lead to
the induction of Akt, which phosphorylates the Forkhead
protein, FOXO1 [33, 34], a major transcription factor for
gluconeogenic gene expression. The phosphorylated form
of FOXO1 is translocated from the nucleus to the cytosol
(Figure 2(b)).
FOXO proteins have been reported to modulate a variety
of cellular responses depending on the cell type [35].
Subfamilies of FOXO proteins include FOXO1 (FKHR),
FOXO3a (FKHR-like1), and FOXO4/AFX (acute lympho-
cytic leukemia-1 fused gene from chromosome X). FOXO1
is a positive trans acting factor that binds to promoter re-
gions within the glucose-6-phosphatase (G6pc) [36], phos-
phoenolpyruvate carboxykinase (Pck1) [37], and perox-
isome proliferator-activated receptor-coactivator-1 alpha
(Ppargc1a) genes [38]. Composed of 655 amino acids,
FOXO1 contains seven phosphorylation sites, namely Thr24,
Ser249, Ser256, Ser319, Ser322, Ser325, and Ser329, which are
modified by a variety of mechanisms (Figure 2(a)). Thr24,
Ser256, and Ser319 are phosphorylated by protein kinase B
(PKB)/Akt (v-akt murine thymoma viral oncogene homolog
1) in response to insulin/insulin growth factor-1 signaling
[39]. Ser249 is phosphorylated by CDK2 (cyclin-dependent
kinase 2) [40], whereas Ser322 and Ser325 are phosphorylated
by CK1 (casein kinase 1) [41]. Lastly, Ser329 is phospho-
rylated by the dual-specificity kinase, DYRK1A (dual-spec-
ificity tyrosine-phosphorylated and regulated kinase 1A)
[42].
As a result of Thr24, Ser256, and Ser319 phosphorylation
[39], FOXO1 is exported from the nucleus to the cytoplasm
[43] where it binds 14-3-3 proteins. Once bound, FOXO1
is retained in the cytoplasm and targeted for proteaso-
mal degradation, preventing its reentry into the nucleus
(Figure 2(b)) [44–46]. Thus, phosphorylation and ubiqui-
tination are important post-translational modifications of
FOXO1 that are critical for its degradation and, ultimately,
its regulation.
The transcriptional activities of FOXO1 are also con-
trolled by its acetylation status. Acetylation by cAMP-re-
sponse element-binding protein-binding protein (CBP) at-
tenuates FOXO1 transcriptional activity [47]. Several acety-
lation sites have been identified in FOXO1, namely, Lys242,
Lys245, and Lys262 [48] (Figure 2(a)). Following acetylation,
the positive charges associated with these lysine residues are
eliminated, inhibiting FOXO1 interaction with DNA and
reducing the ability of this transcription factor to recognize
its own cis element, including the insulin-response element,
in some target genes [15]. In addition, FOXO1 acetylation
has been linked with increased phosphorylation at Ser253 by
Akt [48, 49], which further decreases DNA binding. This
indicates that the interplay between two types of PTMs reg-
ulates the DNA binding activity of FOXO1. On the contrary,
deacetylation of FOXO1 is catalyzed by Sirtuin 1 (SIRT1),
an NAD(+)-dependent deacetylase [47]. The transcriptional
activity of FOXO1 is enhanced by resveratrol-activated SIRT1
resulting in the increase in the hepatic gluconeogenesis [50,
51].
A positive correlation between O-GlcNAcylation and in-
sulin resistance has been demonstrated. Because O-GlcNAc
modifications can also occur on many phosphorylation
sites, it has been postulated that increased O-GlcNAc may
hinder phosphorylation events that normally occur as a
result of insulin signaling. This altered regulation can lead to
insulin resistance [52]. Indeed, serine and threonine residues
within FOXO1 have been shown to be modified by O-
GlcNAcylation (Figure 2(a)), resulting in increased tran-
scription of G6pc and Ppargc1a, as well as genes involved
in the detoxification of reactive oxygen species (ROS) [53–
55]. This eﬀect is independent of FOXO1 subcellular distri-
bution [53]. Presumably, FOXO1 glycosylation could cause a
conformational change in FOXO1 and aﬀect its aﬃnity for
DNA, which would have an impact on its intrinsic activity
and interaction with other cofactors [54]. Modification of
FOXO1 by O-GlcNAcylation has been observed in the liver
of streptozotocin-induced diabetic animals, suggesting that
this modification may be associated with hyperglycemia
[53]. Indeed, chronic hyperglycemia can lead to hypergly-
cosylation of FOXO1, thus inducing G6pc [53], Pck1 [54]
and Ppargc1a genes [55], and causing further production
of hepatic glucose. These observations suggest that FOXO1
O-GlcNAcylation is a major underlying cause of hepatic
glucose overproduction in T2DM [53]. In the hyperglycemic
state, O-GlcNAcylated PGC-1α recruits OGT to FOXO1; the
associated OGT glycosylates FOXO1 and increases its tran-
scriptional activity [56].
cAMP-response-element- (CRE-) binding protein
(CREB) is another important transcription factor that stim-
ulates gluconeogenesis. CREB directly binds to the pro-
moters of G6pc and Pck1 genes or increases gluconeogenesis
by upregulating Ppargc1a gene expression [57]. CREB is
phosphorylated at Ser133 in the transactivation domain by
cAMP-dependent protein kinase (PKA), a modification
that increases CREB transcriptional activity [58, 59]. As its
name suggests, CREB is phosphorylated and activated in
response to hormonal stimuli (e.g., glucagon) that activate
adenylyl cyclase and thereby increase the intracellular
concentration of cAMP. Binding of cAMP to PKA releases
the catalytic domain of PKA from the holoenzyme, allowing
it to translocate to nucleus and phosphorylate CREB [60].
In addition, phosphorylation of CREB at Ser133 promotes
association with CBP/p300 [61] which upregulates CREB
target gene expression by acetylating nucleosomal histones
[62, 63] and recruiting RNA polymerase II complexes
[64, 65]. By contrast, CaMKII (calcium- and calmodulin-
dependent kinase II) induces phosphorylation at Ser142
in the transactivation domain [66], a modification that
inhibits CREB activity by disrupting CREB interaction with
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Figure 2: Continued.
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Figure 2: Post-translational modifications (PTMs) of transcription factors. (a) The positions of PTM sites in the human FOXO1, SREBP-1c,
and NF-κB p65 subunit.The positions of PTM sites and the implicated modifying enzymes are shown. (+) and (–) represent activation
and inhibition of the transcriptional activity of transcription factors, respectively. L1-2, nuclear localization sequences; E1-3, nuclear
export sequences; DBD, DNA-binding domain; TAD, transactivation domain; RHD, Rel homology domain; NLS, nuclear localization
sequence; TAD, transactivation domain. (b) Regulation of FOXO1 nucleocytoplasmic shuttling and transcriptional activity by PTMs in
liver. (c) Regulation of transcription factor activities by PTMs in pancreatic β cells. P, phosphate group; Ac, acetyl group; G, O-linked-N-
acetylglucosamine; Ub, ubiquitin; S, SUMO; Akt, v-akt murine thymoma viral oncogene homolog 1 (also known as protein kinase B [PKB]);
SGK, serum/glucocorticoid-regulated kinase; CK1, casein kinase 1; DYRK1A, dual-specificity tyrosine-phosphorylated and regulated kinase1
A; CDK2, cyclin-dependent kinase 2. PI3K, phosphoinositide-3-kinase; PDK, phosphatidylinositol-dependent protein kinase; OGT, O-
linked N-acetylglucosamine (GlcNAc) transferase; MAPK1/3, mitogen-activated protein kinase 1/3; Ubc9, ubiquitin conjugating enzyme
9; p300, E1A-binding protein p300; CBP, CREB-binding protein; SIRT1, sirtuin 1; PKA, protein kinase A; cAMP, cyclic adenosine
monophosphate; SIK, salt-inducible kinase; GSK-3, glycogen synthase kinase-3; JNK, c-Jun N-terminal kinase; PCAF, CBP/p300-associated
factor; MSK1, mitogen/stress-activated protein kinase 1; PKCζ , protein kinase Cζ ; IKK, I kappa B kinase; CK2, casein kinase 2; TBK1,
tank-binding kinase 1; SOCS-1, suppressor of cytokine signaling 1; HBP, hexosamine biosynthesis pathway; OGA, O-GlcNAcase; PDX1,
pancreatic and duodenal homeobox 1; NeuroD, neurogenic diﬀerentiation; MafA, v-maf (maf musculoaponeurotic fibrosarcoma) oncogene
homolog A.
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CBP/p300 [67]. DNA damage-mediated phosphorylation
of CREB at Ser111 and Ser121 by AMT (ataxia-telangiectasia
mutated) also inhibits CREB activity by blocking CREB-CBP
interaction [68, 69].
CRTC2 (CREB-regulated transcription coactivator 2)
interacts with the bZIP domain of CREB and thereby induces
its activity [70, 71]. The resulting CRTC2-CREB complex
binds to cis elements in the promoters of G6pc, Pck1, and
Ppargc1a genes [72, 73]. CRTC2 is also regulated by O-
GlcNAcylation [74]. Further research is needed to elucidate
the molecular mechanisms and site-specific roles of O-
GlcNAcylation in relation to phosphorylation or other types
of PTMs in terms of glucotoxicity, insulin resistance, and
T2DM.
3.1.2. Modification of Transcription Factors That Regulate
Lipid Metabolism Genes. NAFLD has become a common
chronic disease due to western style diets. This disease
manifests as a simple accumulation of triglycerides in he-
patocytes (hepatic steatosis) or as steatohepatitis, which is
accompanied by inflammation, fibrosis, cirrhosis, and hepa-
tocellular carcinoma in severe cases. It has now become clear
that accumulation of triglycerides in hepatocytes is corre-
lated with T2DM, obesity, and insulin resistance. Steatosis
is caused by an imbalance between lipid availability and
disposal. Triglyceride accumulation in hepatocytes reflects
dietary fatty acid intake, increased lipolysis in adipose tissue,
or de novo lipogenesis. On the other hand, hepatic tri-
glyceride levels are decreased by β-oxidation of fatty acid
in the hepatocytes and triglyceride secretion with very low-
density lipoproteins (VLDLs). In nonalcoholic fatty liver
disease patients, the ratio of lipogenesis to VLDL-packaged
triglyceride secretion is up to 25–30%, a substantial increase
compared to the normal range of 2–5% [75, 76].
The expression of lipogenic enzymes is mainly controlled
at the transcriptional level in the hyperinsulinemic and hy-
perglycemic state. Two major transcription factors, sterol
regulatory element binding protein-1c (SREBP-1c) and car-
bohydrate response element binding protein (ChREBP), are
well known to be involved in these states [77].
SREBP-1c is a member of the basic-helix-loop-helix-
leucine zipper (bHLH-LZ) family of transcription factors. It
is synthesized as an inactive form embedded in the mem-
branes of the ER and is activated in the Golgi apparatus by
proteolytic cleavage. The resulting N-terminal domain cleav-
age fragment (nSREBP-1c), which is the transcriptionally
active form, is translocated to the nucleus. SREBP1a, which is
expressed from anmRNA that overlaps that of SREBP-1c and
diﬀers from SREBP-1c only at the N-terminus, and SREBP-
2, which is the product of a separate gene, regulate the ex-
pression of cholesterol synthesis genes [78]. Expression of
the SREBP-1c gene and maturation and stability of SREBP-
1c protein are regulated by insulin through the PI3K-PDK1-
PKB/Akt pathway [79, 80]. PKB/Akt kinase phosphorylates
and inhibits glycogen synthase kinase-3 (GSK3), whereas
the dephosphorylated form of GSK3 phosphorylates Thr426,
Ser430, and Ser434 of nSREBP-1a, causing degradation by
ubiquitination through the ubiquitin ligase, FBW7 (F-box
and WD repeat domain containing 7) [81]. Similarly, phos-
phorylation of nSREBP1c has been reported [81, 82]. Ser117
of SREBP-1a and Ser93 of SREBP-1c are phosphorylated
by mitogen-activated protein kinase 1/3, and mutation of
these sites abolishes insulin-induced transcriptional activity
(Figure 2(a)) [83].
By contrast, cAMP might act through PKA to regulate
SREBP-1c processing. Phosphorylation of Ser338 of SREBP-
1a and Ser314 of SREBP-1c by PKA reduces the transcrip-
tional activities of the corresponding transcription factors
(Figure 2(a)) [84]. In addition, the nonhydrolyzable PKA
activator, dibutyryl-cAMP, downregulates the proteolytic
processing of SREBP-1a [85]. These results indicate that
insulin and glucagon also modulate the transcriptional activ-
ity of SREBP-1c through phosphorylation. Salt-inducible
kinase, a member of the AMP-activated protein kinase
(AMPK) family, phosphorylates Ser329 of SREBP-1a and
reduces lipogenic gene expression (Figure 2(a)) [86].
Modification of SREBP-1a at Lys123 and Lys418 by Ubc9,
an SUMO-1-conjugating enzyme, reduces its transcrip-
tional activity (Figure 2(a)). However, ubiquitination and
SUMOylation do not compete for the same Lys residues,
and SUMOylation does not aﬀect ubiquitination-mediated
SREBP degradation and stability [87].
CBP/p300-mediated acetylation of SREBP-1c increases
its stability [88]. Lys289 and Lys309 residues near and within
the DNA-binding domain of SREBP-1c, respectively, are
acetylated by p300 and deacetylated by SIRT1 (Figure 2(a))
[89]. Levels of acetylated SREBP-1c are increased in fed mice,
diet-induced obese mice, and insulin- and glucose-treat-
ed HepG2 cells. SIRT1 overexpression decreases SREBP-1c
acetylation level and protein stability, causing a reduction in
lipogenic gene expression [89].
ChREBP, which is also a member of the bHLH-LZ (leu-
cine zipper) family of transcription factors, is the second
of the two major transcription factors shown to induce
glycolytic and lipogenic genes in hepatocytes [90]. ChREBP,
also known as MLXIPL (MLX interacting proteinlike), forms
a heterodimer with the bHLH-LZ protein Mlx (MAX-like
protein X) that binds the carbohydrate response element
of various glucose-responsive genes, including liver type
pyruvate kinase (Pklr), fatty acid synthase (Fasn), and
acetyl-CoA carboxylase 1 (Acc1) [91]. Nuclear localization
of ChREBP is induced by high glucose. In starvation,
glucagon increases intracellular cAMP concentrations and
activates PKA. Phosphorylation of ChREBP by PKA at
Ser196 prevents nuclear localization, whereas PKA-mediated
phosphorylation at Thr666 inhibits DNA binding [92]. In
addition, phosphorylation of Ser568 of ChREBP by AMPK
decreases ChREBP transcriptional activity [93]. In contrast,
xylulose-5-phosphate generated from glucose through the
hexose monophosphate shunt activates protein phosphatase
2A delta, which dephosphorylates ChREBP and increases
lipogenesis [94]. However, the regulation of ChREBP by
phosphorylation and dephosphorylation remains controver-
sial [95, 96].
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A recent study has shown that by increasing the stability
and transcriptional activity of ChREBP, O-GlcNAcylation of
ChREBP in the hyperglycemic state is responsible for fatty
acid synthesis in the mouse liver [97].
3.2. β-Cell Dysfunction and Pancreatic Failure. The pancreas
maintains normal blood glucose levels by regulating insulin
and glucagon secretion. Insulin, an anabolic hormone, mod-
ulates a variety of biological processes and metabolic path-
ways, including cell survival and proliferation, glycogen
synthesis, protein synthesis, and glucose uptake into skeletal
muscle and adipocytes. In an attempt to overcome the reduc-
tion in insulin activity that occurs during insulin resistance,
the number of β cells increases, resulting in a compensatory
hypersecretion of insulin. As the compensation fails, the β-
cell phenotype is disturbed, causing a reduction in β-cell
mass via apoptosis [98].
FOXO1 has been shown to modulate pancreatic β-cell
development, proliferation, maintenance, expansion, and
apoptosis [99, 100]. β-cell failure was observed in IRS2-
deficient mice [101] and FOXO1S253A transgenic mice [102]
which exhibited decreased or nonfunctional FOXO1 phos-
phorylation, respectively. Interestingly, FOXO1 haplodefi-
ciency partially restored β-cell proliferation in thesemice and
increased the expression of pancreatic and duodenal home-
obox 1 (Pdx1) [101] (Figure 2(c)), a critical transcription
factor involved in β-cell diﬀerentiation, development, and
cellular function [103]. In addition, by binding the Foxa2 site
within the Pdx1 promoter, FOXO1 can inhibit the expression
of this crucial transcription factor [101].
FOXO1 also regulates the subcellular distribution of
PDX1 [104] (Figure 2(c)). Nucleocytoplasmic translocation
of PDX1 during hyperglycemia-induced oxidative stress oc-
curs in a Jun N-terminal-kinase- (JNK-) dependent manner,
resulting in β-cell failure [105]. JNK activation during these
conditions results in decreased Akt activity and subsequent
FOXO1 hypophosphorylation, leading to PDX1 transloca-
tion to the cytosol [104]. In support of this, infection of
HIT-T15 cells with adenovirus expressing wild-type FOXO1
led to PDX1 translocation from the nucleus to the cytosol
in the absence of H2O2 treatment [104]. The mechanism by
which nuclear FOXO1 aﬀects PDX1 translocation remains
unknown although reports have suggested that the acetyla-
tion status of the two proteins may be responsible [104].
Acetylation and deacetylation of FOXO1 are modulated
by CBP/p300 and SIRT1, respectively. Transgenic mice bear-
ing a pancreatic β-cell-specific, SIRT1-overexpressing trans-
gene (BESTO) display improved glucose tolerance and en-
hanced glucose-stimulated insulin secretion [106]. In addi-
tion, oxidative stress-mediated FOXO1 deacetylation induces
the expression of neurogenic diﬀerentiation (NeuroD) and
v-maf (mafmusculoaponeurotic fibrosarcoma) oncogene
homolog A (MafA) [107], which play roles in preserving
insulin secretion in response to glucose and thereby promote
β-cell compensation. However, the deacetylated form of
FOXO1 is more easily degraded by ubiquitination than the
acetylated form, suggesting that acetylation status regulates
the stability and transcriptional activity of this protein.
In contrast, deacetylation of the phosphorylation-defective
ADA-FOXO1 mutant, which is constitutively nuclear by
virtue of mutation of Thr24 and Ser316 to Ala(A) and Ser253
to Asp(D), does not aﬀect transcriptional activity [107],
indicating that the transcriptional activity of FOXO1 is
independent of its phosphorylation status.
In the pancreas, glucose-induced insulin gene tran-
scription is mediated by three β-cell-specific transcription
factors: NeuroD1, PDX1, and MafA [103]. NeuroD1 and
PDX1 are OGlcNAcylated and translocated to nucleus under
high-glucose conditions, exhibiting increased DNA-binding
activity and promoting insulin gene expression and insulin
secretion in mouse insulinoma 6 (MIN6) cells [108, 109]. In
addition, in the Gato-Kakizaki rat model of T2DM, the levels
of O-GlcNAcylated proteins, especially those of PDX1 and
O-GlcNAc transferase, were elevated in whole pancreas and
islets of Langerhans [110].
The transcriptional activities of both PDX1 andNeuroD1
are regulated by phosphorylation upon glucose stimulation
[111, 112]. In response to glucose and insulin stimulation,
PDX1 is phosphorylated by stress-activated protein kinase 2
(SAPK2); phosphorylation by PI3K induces nuclear translo-
cation and transcriptional activation [113–115]. SUMOyla-
tion causes nuclear translocation of PDX1 and increases its
stability [116]. In contrast, phosphorylation of Ser61 and/or
Ser66 by GSK3 during oxidative stress promotes PDX1
degradation [117].
3.3. Inflammatory Response of Macrophages. One of the risk
factors for obesity-induced insulin resistance and diabetes is
inflammation. Inflammatory gene expression in hepatocytes
induces insulin resistance [118]. Hepatic steatosis often
accompanies abdominal adiposity, and inflammation plays
a pivotal role in the progression of nonalcoholic fatty liver
disease. In the obese state, increased proinflammatory sub-
stances from abdominal fat might initiate hepatic inflam-
mation and steatosis [119], highlighting the importance of
understanding the role of macrophages in the initiation
of obesity-induced insulin resistance in adipose tissue. En-
largement of adipose tissue as a result of excess dietary
intake induces hypoxic conditions and ER stress, which are
accompanied by nuclear factor-kappa B (NF-κB)- and JNK1-
mediated upregulation of inflammatory genes [120, 121].
Once activated, NF-κB and JNK1 increase the production
of various cytokines and chemokines from adipocytes, in-
cluding tumor necrosis factor (TNF)-α, interleukin (IL)-6,
monocyte chemotactic protein (MCP)-1, and plasminogen
activator inhibitor-1. These molecules play key roles in the
recruitment and infiltration of macrophages into adipocytes
[122–125]. In fact, IL-6 has been reported to regulate the
development of insulin resistance [126]. In addition, MCP-
1 has been reported to increase during high-fat diet-induced
obesity, thereby contributing to macrophage infiltration
into adipose tissue [127]. Macrophages produce proinflam-
matory cytokines that amplify the inflammatory state in
neighboring adipocytes, leading to the secretion of other
mediators, such as adipokines and free fatty acids. Free fatty
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acids enter the circulation to promote insulin resistance in
hepatocytes and myocytes [128, 129].
NF-κB is a master regulator of the expression of genes
involved in the inflammatory response. NF-κB is a multi-
subunit protein variably consisting of p50, p52, p65, c-Rel,
and Rel B; p65 is the major target of protein modification
[130] (Figure 2(a)). This subunit is acetylated at Lys221 by
CBP/p300 and deacetylated by histone deacetylase 3 or
SIRT1 during inflammation [131, 132]. NF-κB is also a key
mediator of TNF-α-induced IL-6 gene expression [131, 133].
Notably, an SIRT1 activator was shown to attenuate the TNF-
α-induced inflammatory signal. Conversely, SIRT1 knock-
down in 3T3-L1 adipocytes using small inhibitory RNAs
increased NF-κB acetylation and enhanced the transcription
of inflammatory genes, causing insulin resistance [134, 135].
By contrast, acetylation of Lys122/Lys123 of the p65 subunit by
CBP/p300 or CBP/p300-associated factor (PCAF) decreased
NF-κB DNA-binding ability and promoted NF-κB nuclear
export and interaction with IκBα, ultimately, attenuating
its transcriptional activity [136, 137]. Taken together, these
results indicate that acetylation of specific lysine residues on
p65 confers diﬀerent functional consequences.
Another modification that occurs on p65 is phosphoryla-
tion. Mitogen- and stress-activated protein kinase-1 (MSK1)
is a nuclear kinase that phosphorylates Ser276 of p65. Treat-
ment of cells with the MSK1 inhibitor H89 has been shown
to block TNF-α-induced phosphorylation of p65 in vivo.
TNF-α promotes the interaction between p65 and MSK1,
which is recruited to the IL-6 promoter [138]. P65 can also
be phosphorylated by protein kinase Cζ (PKCζ) through
TNF-α signaling. Phosphorylation of p65 at Ser311 promotes
complex formation with CBP, increasing complex binding to
the IL-6 promoter [139]. In addition, many inflammatory
stimuli induce p65 phosphorylation at Ser529/Ser536, thereby
increasing the transcriptional activity of NF-κB [140–142].
In response to cytokines, Thr254 of p65 is phosphorylated
by an unknown kinase. Once phosphorylated, p65 forms a
complex with Pin1, preventing binding to IκB and causing
nuclear localization, resulting in greater NF-κB stability and
activity [143].
The stability of p65 is also regulated by the ubiquitin-
proteasome pathway. Treatment of cells with MG132 (a pro-
teasome inhibitor) and His-Ubiquitin resulted in p65 polyu-
biquitination via interaction with suppressor of cytokine
signaling (SOCS)-1. This ubiquitination event was negatively
regulated by Pin-1 and increased the stability of p65- andNF-
κB-dependent gene expression [137, 143].
TNF-α was recently reported to induce polyubiquitina-
tion of Lys195 in p65 and decrease the transcriptional activity
of NF-κB by promoting its degradation. This eﬀect of
TNF-α on p65 appears contradictory but presumably reflects
an important regulatory mechanism; that is, persistent ac-
tivation of p65 by phosphorylation may be terminated by
ubiquitination [144].
The expression of glycosyl transferase and NF-κB target
genes is regulated by either TNF-α or hyperglycemia [145–
147]. O-GlcNAcylation of p65, which occurs on Thr352,
decreases p65 interaction with IκBα, resulting in increased
NF-κB transcriptional activity during hyperglycemia [146,
147].
3.4. Free Fatty Acids-Induced Insulin Resistance in Muscle.
Skeletal muscle is one of the main target tissues which re-
spond to insulin and other hormones [148]. Glucose uptake
by muscle is stimulated by insulin. In patients with NAFLD,
elevated plasma free fatty acids (FFAs) levels are responsible
for insulin resistance [149, 150] causing a decrease in the
insulin-stimulated glucose uptake, glycogen synthesis [151],
and PI3K activity in skeletal muscle [152].
Elevated FFA in the blood causes accumulation of tria-
cylglycerol (TG) in the muscle [153], which is shown to be
associated with increased intracellular diacylglycerol (DAG),
ceramides, and long-chain acyl-coenzyme A (LCA-CoA).
These molecules induce insulin resistance by activating ser-
ine protein kinase C (PKC) [154]. This kinase inhibits
PI3K activities by phosphorylating Ser/Thr residue of IRS-1
causing an inhibition of the insulin-stimulated translocation
of the glucose transporter type 4 isoform (GLUT4) [155].
Phosphorylation of IκB by PKC dissociates IκB from NF-
κB and thereby translocates NF-κB to nucleus to upregulate
proinflammatory TNFα gene [154]. NF-κB is linked to fatty
acid-induced impairment of insulin action in muscle [156,
157].
The increased TG in muscle may be potentially toxic to
skeletal muscle presumably because of ROS overproduction
which inhibits the insulin-stimulated Akt phosphorylation
on Ser residue [158]. ROS also stimulates Thr phosphory-
lation of JNK, a kinase linked to insulin resistance [159]. An
elevated TG is associated with reduced mitochondrial oxida-
tive capacity in skeletal muscles as indicated by lower mito-
chondrial density, reduced capacity of electron transport,
and reduced activities of oxidative enzymes [160]. Further
researches are necessary to understand the contribution of
PTM of transcription factor in the development of insulin
resistance in muscle.
3.5. Adipokine Gene Expression and Secretion from Adipose
Tissue. Contribution of adipose tissue in the maintenance
of whole body insulin sensitivity is critical. Adipogenesis
is a tightly regulated process that involves the complicated
interrelationship of various transcription factors. One of the
pivotal transcription factors is PPARγ, an essential factor
of development and function [161, 162]. Hormonal stimuli
to the preadipocyte trigger the expression of C/EBPβ [163]
which activates the expression of two master transcription
factors, C/EBPα and PPARγ [164]. PPARγ can induce adi-
pogenesis in C/EBPα–/– MEFs (mouse embryonic fibroblast)
[165], whereas C/EBPα is unable to do the same action in
PPARγ–/– MEFs [166]. These results indicate that PPARγ
plays a central role in adipogenesis.
Mitogen-activated protein (MAP) kinase induces the
phosphorylation of Ser112 of PPARγ resulting in the reduc-
tion of transcriptional activity. This observation is supported
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by a study [167] which showed that PPARγ activity was not
decreased by MAP kinase when Ser112 was replaced by Ala.
Furthermore, treatment of PD98059, an inhibitor of MAP
kinase, abolished the phosphorylation of PPARγ [167].
Adipocytes store triglycerides, which are an abundant
source of energy, and secrete adipokines such as adiponectin,
leptin, resistin, and retinol-binding protein 4 [168]. The
expression and secretion of these adipokines are regulated
by PTM of various transcription factors in the context of
obesity.
One such factor is FOXO1, which regulates adiponectin
expression. In FOXO1 haplodeficient animals, adiponectin
gene expression is significantly reduced [169]. In fact, two
FOXO1 response elements have been identified in the
adiponectin promoter [170]. Moreover, SIRT1 was demon-
strated to increase the interaction between FOXO1 and
C/EBPα and enhance subsequent binding to the adiponectin
promoter [170]. These results suggest that FOXO1 deacety-
lation plays an important role in upregulating adiponectin
expression. Adiponectin increases insulin sensitivity by pro-
moting fatty acid oxidation in an AMPK and peroxisome
proliferator-activated receptor-α-dependent manner [171].
The activity of Sp1, a ubiquitously expressed transcrip-
tion factor that regulates most housekeeping genes, has been
shown to be controlled by PTM [172]. In fact, Sp1 was the
first transcription factor shown to be O-GlcNAcylated [173].
When O-GlcNAcylated, Sp1 is less phosphorylated and is
protected from proteasomal degradation [174]. Presumably,
the transcriptional activity of Sp1may vary depending on the
site of O-GlcNAcylation [21].
In 3T3-L1 and primary cultured adipocytes, glucose
increases Sp1 O-GlcNAcylation and upregulates expression
of leptin [175, 176]. Although leptin controls appetite, it is
considered a proinflammatory adipokine [177].
Resistin gene expression is increased by glucosamine
infusion in rats [178], whereas treatment of 3T3-L1 adi-
pocytes with troglitazone results in decreased gene expres-
sion due to a reduction in Sp1 O-GlcNAcylation [179].
These experiments indicate that insulin resistance induced
by chronic hyperglycemia can be modulated by O-GlcNA-
cylation of Sp1. Interestingly, O-GlcNAcylated Sp1 increases
the expression of both leptin and resistin [180].
Perspective
The epidemics of obesity and accompanying metabolic con-
ditions, such as T2DM, nonalcoholic fatty liver disease, and
cardiovascular diseases—diseases that have been linked to
insulin resistance—will pose enormous social and economic
burdens in the coming decades. In these conditions, a num-
ber of transcription factors become modified and ultimately
play positive or negative roles in regulating specific genes.
The resulting metabolic consequences include increased
hepatic gluconeogenesis, abnormal lipid metabolism and ab-
errant insulin biosynthesis/release from pancreatic β cells,
and adipose tissue reactivity to inflammation.
Recent advances in analyticmethodologies have provided
additional insights into the modifications of transcription
factors involved in metabolic alterations in the context of
insulin resistance. Our understanding of insulin resistance
is further improved by a growing appreciation of crosstalk
between the diﬀerent types of modification. Undoubtedly,
continued research will ultimately lead to the development
of novel therapeutic drugs, as evidenced by these rapid
advances.
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